Literature DB >> 12913007

Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains.

Runxiang Zhao1, Xueqi Fu, Lirong Teng, Qingshan Li, Zhizhuang Joe Zhao.   

Abstract

SHP-2 is an Src homology 2 (SH2) domain-containing tyrosine phosphatase with crucial functions in cell signaling and major pathological implications. It stays inactive in the cytosol and is activated by binding through its SH2 domains to tyrosine-phosphorylated receptors on the cell surface. One such cell surface protein is PZR, which contains two tyrosine-based inhibition motifs responsible for binding of SHP-2. We have generated a glutathione S-transferase fusion protein carrying the tandem tyrosine-based inhibition motifs of PZR, and the protein was tyrosine-phosphorylated by co-expressing c-Src in Escherichia coli cells. The purified phosphoprotein displays a strong binding to SHP-2 and causes its activation in vitro. However, when introduced into NIH 3T3 cells by using a protein delivery reagent, it effectively inhibited the activation of ERK1/2 induced by growth factors and serum but not by phorbol ester, in reminiscence of the effects caused by expression of dominant negative SHP-2 mutants and deletion of functional SHP-2. The data suggest that the exogenously introduced PZR protein specifically binds SHP-2, blocks its translocation, and renders it functionally incompetent. This is further supported by the fact that the phosphorylated PZR protein had no inhibitory effects on fibroblasts derived from mice expressing only a mutant SHP-2 protein lacking most of the N-terminal SH2 domain. This study thus provides a novel and highly specific method to interrupt the function of SHP-2 in cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913007     DOI: 10.1074/jbc.M306136200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling.

Authors:  Ning Wang; Zhe Li; Ronghua Ding; Gerald D Frank; Takaaki Senbonmatsu; Erwin J Landon; Tadashi Inagami; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2006-06-08       Impact factor: 5.157

2.  SHP-2 tyrosine phosphatase in human diseases.

Authors:  Hong Zheng; Shawn Alter; Cheng-Kui Qu
Journal:  Int J Clin Exp Med       Date:  2009-01-30

3.  Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.

Authors:  Bing Yu; Wei Liu; Wen-Mei Yu; Mignon L Loh; Shawn Alter; Olgun Guvench; Alexander D Mackerell; Li-Da Tang; Cheng-Kui Qu
Journal:  Mol Cancer Ther       Date:  2013-07-03       Impact factor: 6.261

4.  Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells.

Authors:  Ken-ichi Kusano; Tamlyn N Thomas; Keigi Fujiwara
Journal:  Endothelium       Date:  2008 May-Jun

5.  Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma.

Authors:  Deshui Jia; Ying Jing; Zhenfeng Zhang; Li Liu; Jie Ding; Fangyu Zhao; Chao Ge; Qifeng Wang; Taoyang Chen; Ming Yao; Jinjun Li; Jianren Gu; Xianghuo He
Journal:  Cell Res       Date:  2013-12-03       Impact factor: 25.617

6.  Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.

Authors:  Dan Xu; Xia Liu; Wen-Mei Yu; Howard J Meyerson; Caiying Guo; Stanton L Gerson; Cheng-Kui Qu
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

7.  Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.

Authors:  Jae-Sung Yi; Sravan Perla; Yan Huang; Kana Mizuno; Frank J Giordano; Alexander A Vinks; Anton M Bennett
Journal:  Cardiovasc Drugs Ther       Date:  2021-03-10       Impact factor: 3.947

8.  Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.

Authors:  Jae-Sung Yi; Sravan Perla; Liz Enyenihi; Anton M Bennett
Journal:  JCI Insight       Date:  2020-08-06

9.  Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.

Authors:  Chun-Yu Liu; Kuen-Feng Chen; Tzu-I Chao; Pei-Yi Chu; Chun-Teng Huang; Tzu-Ting Huang; Hsiu-Ping Yang; Wan-Lun Wang; Chia-Han Lee; Ka-Yi Lau; Wen-Chun Tsai; Jung-Chen Su; Chia-Yun Wu; Ming-Huang Chen; Chung-Wai Shiau; Ling-Ming Tseng
Journal:  J Mol Med (Berl)       Date:  2017-06-04       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.